Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy

The Journal of Immunology(2021)10.4049/jimmunol.2100367Source: DataRank Database

Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy is a research paper published in The Journal of Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 35 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access35 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)OA: bronzeTopics (70)Linked Datasets (4)DataCite Reuse (4)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Judy Chang ORCID,Ashanti Dantanarayana,Ajantha Solomon,Vanessa A. Evans ORCID,Rachel D. Pascoe ORCID

Live enrichment

PubMed:34853078

amfAR, The Foundation for AIDS Research

Grant: 109226-58-RGRL

HHS | NIH | National Institute of Allergy and Infectious Diseases

Grant: UM1AI126611-01

Department of Health | National Health and Medical Research Council

Grant: 1135851

The future of HIV care - long term remission and eliminating co-morbidities

Department of Health | National Health and Medical Research Council

Grant: 1149990

Addressing the major challenges in HIV vaccine and cure research

National Institutes of Health

Grant: 5UM1AI126611-05

Delaney AIDS Research Enterprise to Cure HIV

NIAID NIH HHS

Grant: UM1 AI126611

NIAID NIH HHS

Grant: UM1 AI164560

bronzeLicense: OUP Standard Publication Reuse

publisherhttps://www.jimmunol.org/content/jimmunol/208/1/54.full.pdf

publisherhttps://academic.oup.com/jimmunol/article-pdf/208/1/54/61189572/ji2100367.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8702486

https://doi.org/10.4049/jimmunol.2100367

https://pubmed.ncbi.nlm.nih.gov/34853078

Fields of Study

0301 basic medicine03 medical and health sciencesAdultAnti-Retroviral AgentsAntigens, CDAntigens, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCTLA-4 AntigenCells, CulturedDrug SynergismDrug Therapy, CombinationHIV InfectionsHIV Long-Term SurvivorsHIV-1HumansImmune Checkpoint InhibitorsInterleukin-1Lymphocyte ActivationLysosomal-Associated Membrane Protein 1MaleMiddle AgedReceptors, ImmunologicT-Cell Antigen Receptor SpecificityLymphocyte Activation Gene 3 Protein

MeSH Terms

AdultAnti-Retroviral AgentsAntigens, CDAntigens, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCTLA-4 AntigenCells, CulturedDrug SynergismDrug Therapy, CombinationHIV InfectionsHIV Long-Term SurvivorsHIV-1HumansImmune Checkpoint InhibitorsInterleukin-1Lymphocyte ActivationLysosomal-Associated Membrane Protein 1MaleMiddle AgedReceptors, ImmunologicT-Cell Antigen Receptor SpecificityLymphocyte Activation Gene 3 Protein

Keywords

AdultCD4-Positive T-LymphocytesMale610Drug SynergismHIV InfectionsCD8-Positive T-LymphocytesMiddle AgedLymphocyte ActivationHIV Long-Term SurvivorsAnti-Retroviral AgentsAntigens, CDLysosomal-Associated Membrane Protein 1616HIV-1HumansCTLA-4 AntigenDrug Therapy, CombinationAntigens, ViralImmune Checkpoint InhibitorsCells, CulturedInterleukin-1

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 2 of VEGF-A enhances the cytotoxic function of CD4+ cytotoxic T cells via the VEGF-receptor 1/VEGF-receptor 2/AKT/mTOR pathway

10.6084/m9.figshare.26566088figshare

Additional file 2 of VEGF-A enhances the cytotoxic function of CD4+ cytotoxic T cells via the VEGF-receptor 1/VEGF-receptor 2/AKT/mTOR pathway

10.6084/m9.figshare.26566088.v1figshare

Additional file 1 of VEGF-A enhances the cytotoxic function of CD4+ cytotoxic T cells via the VEGF-receptor 1/VEGF-receptor 2/AKT/mTOR pathway

10.6084/m9.figshare.26566085figshare

Additional file 1 of VEGF-A enhances the cytotoxic function of CD4+ cytotoxic T cells via the VEGF-receptor 1/VEGF-receptor 2/AKT/mTOR pathway

10.6084/m9.figshare.26566085.v1figshare